Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Central Hospital Of Bolzano

Verified siteinfo

Italy Via Lorenz Boehler 5, 39100 Bolzano, Italy

  • 11 trials recruiting
  • Plasma cell myeloma · Breast cancer · Plasma cell myeloma refractory
  • Adults and children

About Specializations

Central Hospital Of Bolzano in Bolzano, Italy specialises in clinical trials of conditions such as Plasma cell myeloma, Breast cancer, Plasma cell myeloma refractory, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Musculoskeletal Diseases at Central Hospital Of Bolzano

Clinical research in this area focuses on polymyalgia rheumatica, a painful inflammatory condition that affects the shoulders and hips. The studies are designed to assess whether new treatment approaches can improve symptom control and support more durable remission for people whose disease has recently returned.

  • Evaluating a new therapy strategy for polymyalgia rheumatica
  • Comparing treatment effectiveness in patients with recent relapse
  • Assessing sustained remission as a key outcome of care

This work reflects the Ambulatorio Reumatologico’s interest in improving care for inflammatory rheumatic disease through better long-term disease control.

Neoplasms research in Bolzano

The oncology studies at this site center on high risk non-muscle invasive bladder cancer, with attention to whether adding a new immunotherapy approach can strengthen the effect of standard bladder-directed treatment. The goal is to improve cancer control and reduce the chance that the disease returns or progresses.

  • Testing an immunotherapy-based approach for bladder cancer
  • Comparing cancer response and disease control strategies
  • Studying outcomes that may help prevent recurrence or progression

This research supports efforts to refine treatment for challenging early-stage bladder cancer using combinations of established and newer therapies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Lorenz Boehler 539100 BolzanoItaly
Open in maps ↗
Recruiting now
11 trials
Conditions studied
21
Partner status
Verified site

More sites in BolzanoItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

26 clinical trials

Squamous cell carcinoma of head and neck

Recruiting

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Renal cell carcinoma

Recruiting

Cabozantinib Monitoring for Toxicity Management in Patients with Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Major depression

Recruiting

A study testing intranasal esketamine compared to midazolam for rapidly reducing symptoms of major depressive disorder in adolescents with suicidal thoughts or behavior

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Esketamine
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer+1

Recruiting

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Squamous cell carcinoma of the oral cavity

Recruiting

Study of carboplatin, paclitaxel, and tislelizumab treatment in patients with resectable locally advanced oral cavity squamous cell carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione GONO Plus

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Azienda USL IRCCS Di Reggio Emilia

Plasma cell myeloma refractory

Not yet recruiting

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.